Premium
Haematological and miRNAs (let‐7g, miR‐21, miR‐141) expression modulation profile in serum samples of Human prostate cancer
Author(s) -
JAMES AYORINDE BABATUNDE,
FADAKA ADEWALE OLUWASEUN,
MAGBAGBEOLA OLUBUNMI ABIOLA,
OTURU ABAYOMI,
KOLAWOLE OLUFEMI OMOWUNMI,
OGUNJIMI ADEBISI,
OSHODI TEMITOPE,
HABEEBU MUHAMMED,
ONAWOGA FATIMA OMODEINDE,
AJOGBEJE EBENEZER OLALEYE
Publication year - 2017
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.31.1_supplement.757.12
Subject(s) - microrna , prostate cancer , prostate , medicine , cancer , oncology , hematology , biology , immunology , gene , genetics
MicroRNAs represent a promising new class of biomarkers owing to their inherent stability and resilience. This study investigated the haematological and miRNA expression modulation profile in serum samples of human prostate cancer. Twenty‐two study participants with age range between 59 and 82yeaars were included in the study after informed consent. Blood samples of the participant were obtained and both haematological parameters and miRNA analysis (miR‐21, miR‐141 and let‐7g) were performed using Bc‐3200 auto‐haemalogical analyzer and RT‐PCR. The result shows that there was no correlation between the haematological profile and the modulation of miR‐21, miR‐141 and let‐7g. There was no significant difference in the haematological profile between the healthy control and prostate cancer (PCa) patients. However, miR‐21, miR‐141 and let‐7g (p<0.0001) expressions were significantly up regulated although, miR‐21 expression was more pronounced in the serum of the study participants relative to healthy control group. Analysis of miR‐21, miR‐141 and let‐7g might have clinical utility as a supplement to prostate specific antigen screening.